GLP1R and metabolic dysfunction-associated steatotic liver disease: In a randomized, double-blind, placebo-controlled phase Ib/IIa study (NCT05943886), the GLP-1/FGF21 dual agonist HEC88473 was generally safe and well tolerated in patients with MASLD.